Evidence map›Paper›PMID 37324453›Full record

ArticleFrontiers in pharmacology2023

Adjuvant therapy with Huatan Sanjie Granules improves the prognosis of patients with primary liver cancer: a cohort study and the investigation of its mechanism of action based on network pharmacology.

Juhua Yuan, Abdusami Abdurahman, Ning Cui, Tengteng Hao, Jianhua Zou, Liren Liu, Yu Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Juhua YuanBeijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China.
Abdusami AbdurahmanKey Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ning CuiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Tengteng HaoXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jianhua ZouXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liren LiuKey Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yu WuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xiyuan Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNBeijing Chang'an Integrated Traditional Chinese and Western Medicine Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvant therapyHuatan Sanjie Granules (HSG)network pharmacologyPI3K-Akt/MAPK signaling pathwaysprimary liver carcinoma (PLC)

Identifiers

PMID37324453
PMCPMC10267985
OpenAlexW4379053885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.